Vericel Announces It Has Been Awarded A Ten-Year Contract By The U.S. Biomedical Advanced Research and Development Authority Within HHS; Contract Worth Up To $197M, Effective From April 1

The base period contract of $35 million includes approximately $10 million over the next 12 months for the initial procurement of NexoBrid for the U.S. Strategic National Stockpile and VMI establishment, funding for VMI-related services and initial development activities for a potential expanded NexoBrid indication for the treatment of blast trauma injuries. The ten-year contract, effective as of April 1, 2026, also includes optional awards for additional NexoBrid procurement to expand the Strategic National Stockpile, further clinical development for a potential blast trauma indication, design and validation of a potential U.S based manufacturing facility and the development and procurement of a room temperature stable formulation of NexoBrid.